All In Biotech

Drug Trial Radar · NCT06097364

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 733 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

733

Planned (sponsor's estimate)

Start

Nov 14, 2023

Primary completion

Jul 29, 2029

Study completion Jul 29, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study. This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled). The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study. The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality-of-life and ability to complete routine daily activities

Conditions

  • Follicular Lymphoma (FL)

Interventions

  • OdronextamabDrug

    Administered by intravenous (IV) infusion

  • RituximabDrug

    Administered by IV infusion, or subcutaneous (SC)

  • CyclophosphamideDrug

    Administered by IV infusion

  • DoxorubicinDrug

    Administered by IV infusion

  • VincristineDrug

    Administered by IV infusion

  • Prednisone/PrenisoloneDrug

    Administered orally (PO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapyTime frame: Up to 35 days
  2. Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapyTime frame: Up to 2 years
  3. Severity of TEAEs of odronextamab in combination with chemotherapyTime frame: Up to 2 years
  4. Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)Time frame: Up to 30 months

Locations

145 sites in 17 countries. Site status is shown where the registry gives one.

  • Boca Raton Clinical Research (BRCR) Global

    Plantation, Florida

  • Investigative Clinical Research of Indiana

    Noblesville, Indiana

  • Cancer Center of Kansas

    Wichita, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Henry Ford Health System

    Detroit, Michigan

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Center for Oncology and Blood Disorders

    Houston, Texas

  • Community Cancer Trials of Utah

    Ogden, Utah

  • Prohealth Care Inc

    Waukesha, Wisconsin

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Universitatsklinik fur Kinder und Jungendheilkunde

    Vienna, Austria

  • Klinikum Wels-Grieskirchen

    Wels, Austria

  • Karl Landsteiner University Hospital St. Poelten

    Sankt Pölten, Lower Austria, Austria

  • Medical University of Graz

    Graz, Styria, Austria

  • Landeskrankenhaus Hochsteiermark

    Leoben, Styria, Austria

  • Innsbruck Medical University

    Innsbruck, Tyrol, Austria

  • Kepler University Hospital

    Linz, Upper Austria, Austria

  • Institut Jules Bordet

    Brussels, Belgium

  • Centre Hospitalier Regional de la Citadelle

    Liège, Belgium

  • Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital

    Ghent, Oost-Vlaanderen, Belgium

  • Verenigde Ziekenhuizen van Waas en Durme

    Sint-Niklaas, Oost-Vlaanderen, Belgium

  • Algemeen Ziekenhuis St Jan Brugge Oostende Av

    Bruges, West-Vlaanderen, Belgium

  • AZ Groeninge

    Kortrijk, West-Vlaanderen, Belgium

  • Instituto Nacional de Cancer Jose Alencar Gomes da Silva

    Rio de Janeiro, Brazil

  • Hospital Alemao Oswaldo Cruz

    São Paulo, Brazil

  • AC Camargo Cancer Center

    São Paulo, Brazil

  • Clinical Hospital of Medicine School at Sao Paulo University

    São Paulo, Brazil

  • Casa de Saude Santa Marcelina

    São Paulo, Brazil

  • Hospital Santa Izabel - Santa Casa de Misericordia da Bahia

    Salvador, Estado de Bahia, Brazil

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil

  • Ensino e Terapia de Inovacao Clinica Amo (Etica)

    Salvador, Estado de Bahia, Brazil

  • Hospital Sirio Libanes Brasilia

    Brasília, Federal District, Brazil

  • Instituto DOr de Pesquisa e Ensino Df Star

    Brasília, Federal District, Brazil

  • Instituto Mario Pena de Ensino Pesquisa e Inovacao

    Belo Horizonte, Minas Gerais, Brazil

  • Centro Oncologico do Triangulo (COT) - Uberlandia

    Uberlândia, Minas Gerais, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Liga Norte Riograndense Contra o Cancer

    Natal, Rio Grande do Norte, Brazil

  • Instituto Tacchini de Pesquisa em Saude

    Bento Gonçalves, Rio Grande do Sul, Brazil

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.